Lupin Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a robust financial performance with consolidated revenue reaching ₹279,580.3 million for the full year. Demonstrating commitment to shareholder value, the Board has recommended a final dividend of ₹18 per share, representing a 900% payout on its ₹2 face value equity shares.
Financial Performance Overview
For the financial year ended March 31, 2026, Lupin Limited achieved consolidated revenue from operations of ₹279,580.3 million, a significant growth compared to ₹227,079.0 million in the previous year. The consolidated net profit attributable to the owners of the company for the year stood at ₹53,328.4 million, reflecting the company’s operational strength.
Quarterly Highlights
In the fourth quarter (January-March 2026), the company reported consolidated revenue of ₹74,746.6 million. Profit attributable to owners for this quarter was ₹14,603.4 million. These figures highlight consistent performance in the company’s core pharmaceutical segments throughout the final quarter of the fiscal year.
Strategic Developments
The company continued to execute its growth strategy throughout the year. Notable activities included the slump sale divestments of its India-based OTC and API R&D businesses. Furthermore, the company expanded its global footprint, notably through the acquisition of VISUfarma B.V., concluded in April 2026, and the acquisition of Renascience Pharma Limited by its UK subsidiary.
Dividend Recommendation
Recognizing the solid financial results, the Board of Directors has recommended a dividend of ₹18 per equity share, having a face value of ₹2 each. This dividend recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM). Once approved, the payment will be processed to the entitled shareholders within 30 days of the AGM declaration.
Source: BSE
